Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ABBV-101 |
| Synonyms | |
| Therapy Description |
ABBV-101 is a selective BTK degrader, with activity against mutant BTK, which potentially inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 605). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ABBV-101 | ABBV 101|ABBV101 | BTK inhibitor 39 | ABBV-101 is a selective BTK degrader, with activity against mutant BTK, which potentially inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 605). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BTK C481S | diffuse large B-cell lymphoma | predicted - sensitive | ABBV-101 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ABBV-101 treatment resulted in tumor regression in a cell line xenograft model of diffuse large B-cell lymphoma harboring BTK C481S (Cancer Res (2024) 84 (6_Supplement): 605). | detail... |
| BTK C481S | chronic lymphocytic leukemia | predicted - sensitive | ABBV-101 | Preclinical | Actionable | In a preclinical study, ABBV-101 treatment resulted in reduced tumor burden in the spleen and lymph nodes and decreased leukemic burden in the blood compartment of a mouse model of chronic lymphocytic leukemia harboring BTK C481S (Cancer Res (2024) 84 (6_Supplement): 605). | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05753501 | Phase I | ABBV-101 ABBV-101 + Venetoclax | Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | Active, not recruiting | USA | ITA | ISR | GBR | FRA | ESP | DEU | CAN | 1 |